Home » Topics » BioWorld Science

BioWorld Science
RSS

IMV reports initial data from phase II trial of DPX-Survivac in DLBCL

Sep. 18, 2018

Phase II trial of VK-2809 in patients with NAFLD and elevated LDL-C meets primary endpoint

Sep. 18, 2018

AmpliPhi Biosciences provides updates regarding the development of its bacteriophage therapeutics

Sep. 18, 2018

Sosei suspends HTL-0018318 clinical development following unexpected animal study finding

Sep. 18, 2018

European researchers present new data on compounds against Trypanosoma brucei

Sep. 18, 2018

Aurigene's oral CD47 antagonist AU7R-104 completing IND-enabling studies

Sep. 18, 2018

LEO Pharma and MorphoSys expand strategic alliance

Sep. 18, 2018

Pfizer to evaluate Atomwise's platform for drug discovery

Sep. 18, 2018

GlaxoSmithKline patents hepatitis B e-antigen and/or surface antigen secretion inhibitors

Sep. 18, 2018

CRISPR Therapeutics and ViaCyte partner on gene-edited allogeneic stem cell therapies for diabetes

Sep. 18, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...